67-year legacy in refining technology and secured manufacturing infrastructure Producer of essential raw materials for medical IV solutions, clinical nutrition, and biopharmaceuticals Sustained demand growth driven by population aging and expansion of the bioindustry Expected global synergies with the feed-grade amino acid business
Daesang announced on the 18th that it will expand its global pharmaceutical and bio business by acquiring the German pharmaceutical-grade amino acid specialist “AMINO GmbH” (hereinafter AMINO).
On the 17th, Daesang disclosed that it would acquire 100% of AMINO’s shares for approximately KRW 50.2 billion. The company is currently undergoing the legal approval process related to the acquisition and plans to complete the transaction by March 2026.
AMINO, founded in 1958, is a manufacturer of pharmaceutical-grade amino acids, producing high-purity amino acids used in medical infusion solutions, medical nutrition, cell culture media, and excipients (additives that maintain the form of pharmaceuticals). It operates research facilities and three production plants with a total area of about 6,000㎡ in Frellstedt in northern Germany, and has established a stable supply system with European and global biopharmaceutical companies.
Through this acquisition, Daesang will secure a bridgehead for entering the pharmaceutical-grade amino acid market. In this market, demand for infusion solutions and medical nutrition is increasing by about 10% annually due to population ageing and the expansion of medical infrastructure, while demand for related raw materials is also growing in line with the expansion of the biopharmaceutical industry, including protein, gene, and cell therapies.
In particular, Daesang expects to strengthen its competitiveness even in markets with high technical reliability requirements and high entry barriers by securing AMINO’s core competitiveness in purification technology and its regulatory approval network in Europe. Based on this, Daesang plans to solidify its presence in Europe and gradually expand into the North American and Asian markets.
Daesang also expects to achieve raw material efficiency and business diversification through technological and process synergies with its existing feed-grade amino acid business.
Lim Jeong-bae, CEO of Daesang, said, “This acquisition is a strategic investment to expand into the high value-added pharma-bio sector based on the technological capabilities accumulated in our existing ingredient business. By leveraging AMINO’s purification technology and global network, we will secure differentiated competitiveness in the pharmaceutical-grade amino acid market.”
Kim Sang-jun
AI-translated with ChatGPT. Provided as is; original Korean text prevails.
ⓒ dongA.com. All rights reserved. Reproduction, redistribution, or use for AI training prohibited.
